Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Enfusion, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Enfusion, Inc. (ENFN) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (“Enfusion”) (NYSE: ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation.
What Potential Securities Violations Is BG&G Investigating?
The investigation concerns whether Enfusion’s board of directors breached its fiduciary duties and failed to provide relevant information to its shareholders before the merger.
On January 13, 2025, Enfusion announced that it would be acquired by Clearwater Analytics in a cash and stock deal valued at $1.5 billion.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Enfusion shares, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Enfusion, Inc. (ENFN) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”